News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Investor Believes Roche (RHHBY) May Buy Exelixis, Inc. (EXEL) For Skin Cancer Drug


7/15/2014 7:15:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche (RHHBY +1.3%) has a strong incentive to acquire Exelixis (EXEL +10.7%) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf (vemurafenib). He says that the combo regimen could reach peak sales of $1B and should be priced at a premium to Glaxo's (GSK -0.4%) inferior offering of Tafinlar and Mekinist. He believes it will establish itself as the standard of care as a first-line therapy for BRAF-mutated melanoma.

Help employers find you! Check out all the jobs and post your resume.

Read at Seeking Alpha
Read at The Street.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES